| Code | 2388F | ||||||||||
| MA number | 44/0004/26-S | ||||||||||
| Product Form: | tbl 60x2,5 mg (blis.OPA/Al/PVC/Al) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | TEVA Pharmaceuticals Slovakia s.r.o., Slovakia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 30 | ||||||||||
| Container: | blister OPA/Al/PVC/Al | ||||||||||
| Route of admin.: | Oromucosal use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 20.01.2026 |
| Validity: | 20.01.2031 |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Everolimus Teva 2,5 mg_tbl_01/2026_REG.pdf
|
| PIL: |
PIL_Everolimus Teva 2,5 mg_tbl_01/2026_REG.pdf
|
| Safety feature | Yes |
| Data update: | 27.01.2026 |
